Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
If I recall correctly, this was largely covered up by other failures in the AD SPACE.
Haven't you heard? It's coming. Not like a holiday, or weekend, like the day you discover you're having a kid, or the day you find a $20 in the dryer...
Oh, I didn't know. When did you find out? Is there something you can share that shows it doesn't work?
Tanzi is building the pathway backward, step by step. Probably effective in the long run, but SLOOOWWW to get there.
What happens when the brain is cleared of Amyloid Beta... crickets...
It is relevant...
PRE-084 is a sigma-1 agonist. There is alot of research on this.
This is a bunch of BS. Of course, everyone has the goods. There is no way of knowing without clinical trials and there is certainly alot of research data on A2-73, Sigma 1 agonists, and the use of muscarinic receptors. Tough nut to crack...
Noone knows the Golden answer, yet... only time and money will tell.
A2-73 is more than a sigma-1 agonist. There is a wealth of study around this that provides more information, but don't short the complexity of this compound and what it has to offer. Look at the whole picture.
Maybe this assumption and conclusion...
Define ethical.
That was not the end game for Anavex or me as an investor, and it would be wrong to price in all the other operations into rett alone. If this company is only successful in the rett indication, they should simply cut thier losses and license to a larger company that can absorb all the overhead, not paying millions to the CEO and Accountant for one small indication alone.
Anavex should price according to projected future success in at least one other indication. Revenue now helps fund future operation, but should not support all operations. Don't punish rett patients because we invested in something bigger.
Thanks, George.
NIH funding... How would you compare these results? Did SAVA use any biomarkers or any unusual exclusions or is the 50 patient population random and wild?
Those results look impressive.
What do you think about those results George? It seems like SAVA has alot more momentum and alot less baggage.
Chris was not the original patent holder, nor was Anavex, of either compound.
Half a billion, not bad for a $1.5 billion company... maybe I should have sold all my shares with Sandra and Chris.
There are several coincidental timing issues.
$7-$14?
Government healthcare?
Never understood this argument. Let's have a bunch of preffered shares to deter a potential acquirer. That also makes the stock unattractive to potential investors.
$12 looks like a strong support level.
Nice assumption. Maybe another trial. Seems people always take things from one extreme to the other. Another trial would be a waste if the sample population is diverse and there is a significant correlation to dosing. It is sad that social influences have such a strong impact without basis other than feelings. I hope the TGA approves if this is the case.
Take it that you invested in PRAN too.
Yeah, your right, tax deferred.
Maybe this week. Hope your right this time. A short squeeze would be nice.
Yeah, everyone would want to take it all the time!
Did Dr. Tanzi ever complete the petri dish alzheimers model? Seemed like a cool idea. Makes me wonder about the influence of other systems in the body though.
I believe you only pay taxes on profit, not cost basis.
Let's see how that plays out...
Hmm, do you think someone telegraphed the news? Same old, same old. Why raise capital when you know you have another announcement to make? The answer is not the cabal.
More dillution.
Must be TGD.
SAVA MC $3.27B AVXL MC $1.94B
It's the same old BS with this stock.
Stocks usually go up on good news...
Every time!
Great data with huge market, and only $2.17 Billion market cap.